Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2019, Article ID 4625787, 12 pages
https://doi.org/10.1155/2019/4625787
Research Article

Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France

1Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA 02139, USA
2RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USA
3RTI Health Solutions, 307 Waverley Oaks Road, Suite 101, Waltham, MA 02452, USA
4Department of Haematology, Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, EBMT Paris Study Office, CEREST-TC, Saint-Antoine Hospital, Paris, France

Correspondence should be addressed to Keith L. Davis; gro.itr@sivadlk

Received 6 April 2018; Accepted 16 December 2018; Published 29 January 2019

Academic Editor: Francesco Dazzi

Copyright © 2019 Huamao Mark Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Huamao Mark Lin, Keith L. Davis, James A. Kaye, Katarina Luptakova, Saurabh P. Nagar, and Mohamad Mohty, “Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France,” Advances in Hematology, vol. 2019, Article ID 4625787, 12 pages, 2019. https://doi.org/10.1155/2019/4625787.